Eflimrufusp alfa
- Generic Name
- Eflimrufusp alfa
Efficacy and Safety of RC28-E Versus Aflibercept
Phase 3
Recruiting
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT05727397
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath